In yesterday’s Wall Street session, Viatris Inc. (NASDAQ:VTRS) shares traded at $11.08, down -2.12% from the previous session.
VTRS stock price is now 15.07% away from the 50-day moving average and 3.16% away from the 200-day moving average. The market capitalization of the company currently stands at $13.32B.
With the price target enhanced from $9 to $12, UBS Upgraded its rating from Sell to Neutral for Viatris Inc. (NASDAQ: VTRS). On November 08, 2022, Piper Sandler Upgraded its previous ‘Underweight’ rating to ‘Neutral’ on the stock keeping its target price maintained at $10, while ‘Jefferies’ rates the stock as ‘Hold’.
In other news, van der Meer Mohr Pauline, Director sold 9,440 shares of the company’s stock on Aug 17. The stock was sold for $99,912 at an average price of $10.58. Upon completion of the transaction, the Director now directly owns 20,543 shares in the company, valued at $0.23 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 27, Taddese Menassie sold 8,813 shares of the business’s stock. A total of $106,406 was realized by selling the stock at an average price of $12.07. Insiders disposed of 1,375,093 shares of company stock worth roughly $15.24 million over the past 1 year. A total of 0.21% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VTRS stock. A new stake in Viatris Inc. shares was purchased by BNP PARIBAS ARBITRAGE, SNC during the first quarter worth $18,921,000. POINT72 ASSET MANAGEMENT, L.P. invested $18,702,000 in shares of VTRS during the first quarter. In the first quarter, BROOKFIELD ASSET MANAGEMENT INC. acquired a new stake in Viatris Inc. valued at approximately $12,468,000. QUBE RESEARCH & TECHNOLOGIES LTD acquired a new stake in VTRS for approximately $12,182,000. INVENOMIC CAPITAL MANAGEMENT LP purchased a new stake in VTRS valued at around $11,671,000 in the second quarter. In total, there are 1,326 active investors with 76.50% ownership of the company’s stock.
On Wednesday morning Viatris Inc. (NASDAQ: VTRS) stock kicked off with the opening price of $11.27. During the past 12 months, Viatris Inc. has had a low of $8.42 and a high of $15.60. As of last week, the company has a debt-to-equity ratio of 1.04, a current ratio of 1.60, and a quick ratio of 1.10. The fifty day moving average price for VTRS is $9.63 and a two-hundred day moving average price translates $10.74 for the stock.
The latest earnings results from Viatris Inc. (NASDAQ: VTRS) was released for Jun, 2022. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at $0.88, beating analysts’ expectations of $0.83 by 0.05. This compares to $0.26 EPS in the same period last year. The net profit margin was 4.80% and return on equity was 4.00% for VTRS. The company reported revenue of $4.08 billion for the quarter, compared to $4.54 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -10.1 percent. For the current quarter, analysts expect VTRS to generate $4.14B in revenue.
Moreover, the firm recently paid out its quarterly dividend on 12/16/2022. Investors who held shares on 11/23/2022 were paid a $0.12 dividend. On an annualized basis, this represents a $0.48 dividend and a 4.33% percent yield. There was an ex-dividend date of 11/22/2022 for this dividend. In terms of dividend payout ratio, VTRS is presently at 70.90%.
Viatris Inc.(VTRS) Company Profile
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.